Relay Therapeutics, Inc. (RLAY) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 37 days, typically, give or take 10 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Wed, Nov 4, 2026after close 35 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Tue, May 5, 2026after close 35 8-K
Q4 FY2025Thu, Feb 26, 2026after close 57 8-K
Q3 FY2025Thu, Nov 6, 2025after close 37 8-K
Q2 FY2025Thu, Aug 7, 2025after close 38 8-K
Q1 FY2025Mon, May 5, 2025after close 35 8-K
Q4 FY2024Wed, Feb 26, 2025after close 57 8-K

What they guided beta

Q3 FY2026 "Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies to be featured in oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition; Relay to hold conference call to discuss data and provide regulatory update Shannon Campbell to lead commercial preparations for zovegalisib in breast cancer and vascular anomalies Announced second vascular anomalies program for mutant-selective TIE2 inhibitor Approximately $849 million in cash, cas" exhibit
Q3 FY2026 "The company expects its current cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2029." exhibit
Q1 FY2026 "FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer Presented zovegalisib doublet data at Phase 3 dose in CDK4/6-experienced patients at ESMO TAT, demonstrating 11.1-month median PFS with similar efficacy in kinase and non-kinase mutations Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027 Initiated Phase 1/2 trial of RLY-8161, a NRAS-selective mol" exhibit
Q1 FY2026 "Announced clinical data for zovegalisib plus atirmociclib triplet combination, plans for frontline breast cancer study, and clinical supply agreement with Pfizer o Compelling efficacy and tolerability data presented for zovegalisib triplet in median third-line (3L) patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer o 44% objective response rate (ORR) reported in heavily pre-treated CDK4/6-experienced patients (median 3L) at unoptimized doses and ORR was similar across kinase and non-kinase PIK3CA mutations o Adverse events were consistent with those previously reported by each mol" exhibit
Q1 FY2026 "The company expects its current cash, cash equivalents, and investments will be sufficient to fund its operating expenses and capital expenditure requirements into 2029." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RLAY
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RLAY

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

RLAY earnings date badge

HTML

<a href="https://veritasdata.dev/company/RLAY/"><img src="https://veritasdata.dev/embed/RLAY.svg" alt="RLAY earnings date" width="240" height="56"></a>

Markdown

[![RLAY earnings date](https://veritasdata.dev/embed/RLAY.svg)](https://veritasdata.dev/company/RLAY/)

Script

<script async src="https://veritasdata.dev/embed/RLAY.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RLAY"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.